{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:54Z","timestamp":1786116354019,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00059-025-05353-7","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:12:56Z","timestamp":1765278776000},"page":"311-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding risk associated with the co-use of direct oral anticoagulants and non-dihydropyridine calcium channel blockers: a\u00a0meta-analysis","Blutungsrisiko unter gleichzeitiger Anwendung von direkten oralen Antikoagulanzien und Nichtdihydropyridin-Kalziumkanalblockern: eine Metaanalyse"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-6929","authenticated-orcid":false,"given":"Francinny","family":"Alves Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3215-6291","authenticated-orcid":false,"given":"Elisa","family":"Andrade de Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9661-8539","authenticated-orcid":false,"given":"Clara","family":"Rocha Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0047-027X","authenticated-orcid":false,"given":"Aminah Abr\u00e3o Fauaz","family":"Ritter Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5788-7098","authenticated-orcid":false,"given":"Barbara Antonia","family":"Dups Talah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0637-0387","authenticated-orcid":false,"given":"Artur","family":"de Oliveira Macena L\u00f4bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6634-4138","authenticated-orcid":false,"given":"Antonio Gabriele","family":"Laurinavicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3220-019X","authenticated-orcid":false,"given":"Fernanda","family":"Marciano Consolim-Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"1","key":"5353_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej\u00a0J et\u00a0al (2020) Epidemiologia da fibrila\u00e7\u00e3o atrial no s\u00e9culo XXI. Circ Res 127(1):4\u201320","journal-title":"Circ Res"},{"key":"5353_CR2","doi-asserted-by":"crossref","unstructured":"BOSCH, NA; CIMINI, J.; WALKEY, AJ Fibrila\u00e7\u00e3o Atrial na UTI. Chest, v. 154, n.\u00a06, p.\u00a01424\u20131434, dez. 2018.","DOI":"10.1016\/j.chest.2018.03.040"},{"key":"5353_CR3","unstructured":"HERMANS, BJM et\u00a0al. Novos conceitos em fisiopatologia da fibrila\u00e7\u00e3o atrial. Herzschrittmachertherapie + Elektrofisiologie, 22\u00a0conjuntos. 2022."},{"key":"5353_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jgs.12799","volume":"62","author":"P Sardar","year":"2014","unstructured":"Sardar\u00a0P, Chatterjee\u00a0S, Chaudhari\u00a0S, Lip\u00a0GYH (2014) Novos anticoagulantes orais em adultos idosos: evid\u00eancias de uma meta-an\u00e1lise de ensaios randomizados. J\u00a0Am Geriatr Soc 62:857\u2013864","journal-title":"J Am Geriatr Soc"},{"key":"5353_CR5","doi-asserted-by":"publisher","unstructured":"Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131(7):492-501. https:\/\/doi.org\/10.7326\/0003-4819-131-7-199910050-00003","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"5353_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.jacc.2014.07.967","volume":"64","author":"G Flaker","year":"2014","unstructured":"Flaker\u00a0G, Lopes\u00a0RD, Hylek\u00a0E et\u00a0al (2014) Amiodarona, anticoagula\u00e7\u00e3o e eventos cl\u00ednicos em pacientes com fibrila\u00e7\u00e3o atrial: insights do estudo ARISTOTLE. J\u00a0Am Coll Cardiol 64:1541\u20131550","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5353_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","volume":"4","author":"K Hill","year":"2021","unstructured":"Hill\u00a0K, Sucha\u00a0E, Rhodes\u00a0E, Bota\u00a0S, Hundemer\u00a0GL, Clark\u00a0EG, Canney\u00a0M, Harel\u00a0Z, Wang\u00a0TF, Carrier\u00a0M, Wijeysundera\u00a0HC, Knoll\u00a0G, Sood\u00a0MM (2021) Amiodarone, Verapamil, or Diltiazem use with direct oral anticoagulants and the risk of hemorrhage in older adults. Cjc Open 4(3):315\u2013323. https:\/\/doi.org\/10.1016\/j.cjco.2021.11.002","journal-title":"Cjc Open"},{"issue":"1","key":"5353_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1060028018795140","volume":"53","author":"JW Bartlett","year":"2019","unstructured":"Bartlett\u00a0JW, Renner\u00a0E, Mouland\u00a0E, Barnes\u00a0GD, Kuo\u00a0L, Ha\u00a0NB (2019) Clinical safety outcomes in patients with nonvalvular atrial fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother 53(1):21\u201327. https:\/\/doi.org\/10.1177\/1060028018795140","journal-title":"Ann Pharmacother"},{"issue":"6","key":"5353_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich\u00a0N, Stein\u00a0N, Muszkat\u00a0M (2021) Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther 110(6):1526\u20131536. https:\/\/doi.org\/10.1002\/cpt.2369","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"5353_CR10","doi-asserted-by":"publisher","first-page":"e203593","DOI":"10.1001\/jamanetworkopen.2020.3593","volume":"3","author":"P Pham","year":"2020","unstructured":"Pham\u00a0P et\u00a0al (2020) Association of oral anticoagulants and Verapamil or Diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 3(4):e203593\u20131. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3593","journal-title":"JAMA Netw Open"},{"issue":"4","key":"5353_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","volume":"49","author":"S Hanigan","year":"2020","unstructured":"Hanigan\u00a0S, Das\u00a0J, Pogue\u00a0K, Barnes\u00a0GD, Dorsch\u00a0MP (2020) The real world use of combined P\u2011glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J\u00a0Thromb Thrombolysis 49(4):636\u2013643. https:\/\/doi.org\/10.1007\/s11239-020-02037-3","journal-title":"J Thromb Thrombolysis"},{"issue":"14","key":"5353_CR12","doi-asserted-by":"publisher","first-page":"e025723","DOI":"10.1161\/JAHA.122.025723","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu\u00a0Y, Chang\u00a0AR, Inker\u00a0LA, McAdams-DeMarco\u00a0M, Grams\u00a0ME, Shin\u00a0JI (2022) Concomitant use of Diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J\u00a0Am Heart Assoc 11(14):e25723. https:\/\/doi.org\/10.1161\/JAHA.122.025723","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"5353_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jama.2024.3867","volume":"331","author":"WA Ray","year":"2024","unstructured":"Ray\u00a0WA et\u00a0al (2024) Serious bleeding in patients with atrial fibrillation using Diltiazem with Apixaban or Rivaroxaban. JAMA 331(18):1565\u20131575. https:\/\/doi.org\/10.1001\/jama.2024.3867","journal-title":"JAMA"},{"issue":"3","key":"5353_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10840-022-01355-1","volume":"66","author":"M Shurrab","year":"2023","unstructured":"Shurrab\u00a0M et\u00a0al (2023) Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients. J\u00a0Interv Card Electrophysiol 66(3):629\u2013635. https:\/\/doi.org\/10.1007\/s10840-022-01355-1","journal-title":"J Interv Card Electrophysiol"},{"issue":"8","key":"5353_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","volume":"9","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez\u00a0M, Carnoy\u00a0L, Capiau\u00a0A, Boussery\u00a0K, Mehuys\u00a0E, De Backer\u00a0TL, Steurbaut\u00a0S, Lahousse\u00a0L (2023) Impact of P\u2011glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin\u00a0K antagonist oral anticoagulants: a\u00a0nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 9(8):722\u2013730. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad070","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"5353_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00228-023-03501-8","volume":"79","author":"L Gosselin","year":"2023","unstructured":"Gosselin\u00a0L, Vilcu\u00a0AM, Souty\u00a0C, Steichen\u00a0O, Launay\u00a0T, Conte\u00a0C, Saint-Salvi\u00a0B, Turbelin\u00a0C, Sarazin\u00a0M, Blanchon\u00a0T, Hanslik\u00a0T, Lapeyre-Mestre\u00a0M, Rossignol\u00a0L (2023) Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database. Eur J Clin Pharmacol 79(7):937\u2013945. https:\/\/doi.org\/10.1007\/s00228-023-03501-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"5353_CR17","doi-asserted-by":"publisher","first-page":"e203593","DOI":"10.1001\/jamanetworkopen.2020.3593","volume":"3","author":"P Pham","year":"2020","unstructured":"Pham\u00a0P, Schmidt\u00a0S, Lesko\u00a0L, Lip\u00a0GYH, Brown\u00a0JD (2020) Association of oral anticoagulants and Verapamil or Diltiazem with adverse bleeding events in patients with Nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 3(4):e203593. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.3593","journal-title":"JAMA Netw Open"},{"issue":"5","key":"5353_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell\u00a0J et\u00a0al (2013) Drug-drug interaction studies of cardiovascular drugs involving P\u2011glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor\u00a0Xa inhibitor. Am J Cardiovasc Drugs 13(5):331\u2013342. https:\/\/doi.org\/10.1007\/s40256-013-0029-0","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"5353_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.amjcard.2017.05.026","volume":"120","author":"JB Washam","year":"2017","unstructured":"Washam\u00a0JB et\u00a0al (2017) Efficacy and safety of Rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF trial). Am J Cardiol 120(4):588\u2013594. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.026","journal-title":"Am J Cardiol"},{"key":"5353_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jcph.5","volume":"53","author":"D Kubitza","year":"2013","unstructured":"Kubitza\u00a0D, Becka\u00a0M, Roth\u00a0A et\u00a0al (2013) The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2014an oral, direct Factor\u00a0Xa inhibitor. J\u00a0Clin Pharmacol 53:249\u2013255. https:\/\/doi.org\/10.1002\/jcph.5","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"5353_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom\u00a0JW et\u00a0al (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774\u2013782. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.612812","journal-title":"Circulation"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05353-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-025-05353-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-025-05353-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:17:54Z","timestamp":1786007874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-025-05353-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5353"],"URL":"https:\/\/doi.org\/10.1007\/s00059-025-05353-7","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.\u00a0Alves Kelly, E.\u00a0Andrade de Faria, C.\u00a0Rocha Dantas, A.A.F.\u00a0Ritter Lima, B.A.\u00a0Dups Talah, A.\u00a0de Oliveira Macena L\u00f4bo, A.G.\u00a0Laurinavicius and F.\u00a0Marciano Consolim-Colombo declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}